In treating patients with resectable melanoma, the introduction of effective systemic therapies has dramatically improved our ability to reduce patient’s risk of recurrence and therefore to improve their survival.
Moderated by Dr David Gyorki, VCCC Research & Education Lead for Melanoma and Skin Cancers, this webinar will explain the rationale for the use of systemic therapy in a neoadjuvant setting and highlight emerging data around efficacy, toxicity and prognostic biomarkers.
Professor Georgina Long
Medical Director, Melanoma Institute Australia
Professor Georgina Long leads an extensive clinical trials team and laboratory at the Melanoma Institute Australia with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.
Professor Long has been at the forefront of clinical research in neoadjuvant therapies in melanoma including leading an international neoadjuvant consortium to coordinate clinical activities in this setting to ensure rapid transfer of new data to the clinic.
Dr Michelle Wilkinson
Surgical Oncology Fellow, Peter MacCallum Cancer Centre
Dr Michelle Wilkinson is a surgical oncology fellow training in sarcoma and melanoma with a specialist interest in isolated limb perfusion and oncolytic virotherapy.
To be announced soon
This event will be hosted via the Zoom platform. Zoom is accessible on your computer, tablet or phone via the Zoom app. If you have any issues with this platform on your device, please visit the Zoom support site. Alternatively please contact your IT administrator.
Please note that you will receive the meeting ID via a calendar invitation after registering by Eventbrite. Meeting ID will be released on the day of the event.
